Diabetes

Research examines the effect of time-restricted meals on metabolic health in patients with type 2 diabetes.

Research indicates that the risk of certain conditions becomes significantly increased following a bout of COVID-19.

Novo Nordisk’s Saxenda (liraglutide) and Wegovy (semaglutide) are leading the way for a new crop of drugs that reduce appetite, but the cost-effectiveness is in question with many payers saying no to coverage.

The state's budget includes $100 million for the new program.

Over time, the emotional burden of managing the disease can become overwhelming.

Tirzepatide is a once-weekly subcutaneous injection to treat type 2 diabetes in conjunction with diet and exercise.

As Congress considers legislation that would cap out-of-pocket costs for insulin, Walmart and Civica Rx are taking steps that could make less expensive versions of the diabetes medication more available.

Diabetes patients with a Medicare Advantage plan had poorer health than those on fee-for-service plans

New research supports the safety of automated insulin delivery systems.

New research indicates dulaglutide is effective in improving glycemic control in pediatric patients with diabetes.

An analysis of real-world data from more than 6500 patients compared the risk of fracture for insulin, metformin, and a combination of insulin and metformin.

An analysis of the SEARCH for Youth in Diabetes describes historic and contemporary disparities in insulin pump use for pediatric type 1 diabetes based on racial/ethnic background, household income, and insurance type.

Research indicates use of the SGLT2 inhibitor could reduce risk of developing kidney stones

Rising insulin prices have led department to examine the impetus behind setting prices that many patients can't afford.

Pharmacy residents can aid in effectively improving HbA1c levels in patients.

A do-it-yourself option to replace traditional diabetes management technology is growing in popularity.

Continuous glucose monitoring has many benefits and can improve disease management in for both diabetes types.

The FreeStyle Libre 3 system, billed as the world's smallest, thinnest, and most accurate 14-day glucose sensor, received FDA clearance on May 31 and is expected to be available in participating pharmacies later this year.

Identifying these risk factors can help with early detection of T2D.

Other risk factors include high blood pressure and cardiovascular disease.

Using 21 years of follow-up data from more than 3000 patients with prediabetes, results of the DPPOS study demonstrate metformin use and lifestyle intervention reduced the risk of progressing to T2D, but did little to reduce the long-term risk of cardiovascular disease in these patients.

A systematic review and meta-analysis of 7 trials provide a detailed overview of the reductions in HbA1c and body weight, as well as the safety, of tirzepatide in various doses compared against placebo and other diabetes medications from clinical trials.

A retrospective analysis of more than 25k patients with type 2 diabetes details the impact achieving early glycemic control can have on the risk of cardiovascular disease events among these patients.

Announced on May 13, the approval indicates Eli Lilly and Company's novel dual GLP-1/GIP agonist, tirzepatide (Mounjaro), for use as an adjunct to diet and exercise to improve blood sugar in adult patients with type 2 diabetes.

An analysis of data from more than 3500 individuals followed for more than 20 years provides insight into the impact of food insecurity on risk of cardiometabolic conditions, including obesity and type 2 diabetes.

A review of data presented at ATTD 2022 dissects what features within smartphone applications created to improve diabetes management actually contribute to improved glycemic control.

This valuable service can make a meaningful difference.

The role of altered gut microbiota on functions, ranging from hormone secretion to metabolic function, remains unclear.

Many patients with heart failure do not receive optimal therapy until they present to a hospital with exacerbations.

One in 5 American adults with diabetes don't know that they have the disease.